Delving into the Latest Updates on Morishita Jintan Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Infectious Diseases

Urogenital Diseases

Shared antigen vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Shared antigen vaccine	1

Top 5 Target	Count

HPV E7	1

A dose-ranging study to evaluate the effects of probiotics-containing foods on improving bowel movement -a randomized double-blind placebo-controlled study- - A dose-ranging study to evaluate the effects of probiotics-containing foods on improving bowel movement -a randomized double-blind placebo-controlled study-

Start Date31 Oct 2023

Sponsor / Collaborator

Morishita Jintan Co., Ltd.

JPRN-UMIN000042505 / Recruiting

Investigation of effects of blackcurrant extract on suppression of myopia progression - Investigation of effects of blackcurrant extract on suppression of myopia progression

Start Date29 Sep 2021

Sponsor / Collaborator

Morishita Jintan Co., Ltd.

100 Clinical Results associated with Morishita Jintan Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Morishita Jintan Co., Ltd.

Login to view more data

51

Literatures (Medical) associated with Morishita Jintan Co., Ltd.

01 Jan 2024·Bioscience of Microbiota, Food and Health

Effects of blackcurrant extract on indole and ammonia productions in an <i>in vitro</i> human fecal culture model

Article

Author: INAGAKI, Mizuho ; YAMAGUCHI, Taiki ; MITSUNAGA, Tohru ; NAKAMURA, Kohei ; OKAYAMA, Miho ; HAYASHI, Takayuki ; ISHIGURO, Nanami ; KOHNO, Mamiko ; KAWAKAMI, Hirosato

Blackcurrant is available as a traditional medicine in Europe. However, the detailed effects of blackcurrant on the human gut microbiota remain unknown. In this study, we investigated the prebiotic effects of a blackcurrant extract using a human fecal culture model in six healthy subjects. Feces were individually inoculated into a medium with or without the blackcurrant extract and then fermented for 48 hr under anaerobic conditions. The results obtained from analysis of samples from the fermented medium demonstrated that after 48 hr of fermentation, the pH of the medium with the blackcurrant extract was significantly decreased (control, 6.62 ± 0.20; blackcurrant extract, 6.41 ± 0.33; p=0.0312). A 16S rRNA gene sequencing analysis of the microbiota of the fermented medium showed a significant increase in the relative abundance of Bifidobacteriaceae. In measuring the concentrations of putrefactive components in the fermented medium, we found that the blackcurrant extract significantly reduced ammonia levels and displayed a tendency toward reduced indole levels. Our results suggest that blackcurrant extract could be a potential ingredient for relief of putrefactive components in the gut.

01 Jan 2024·Journal of Natural Medicines

Inhibitory effect of trans-tiliroside on very low-density lipoprotein secretion in HepG2 cells and mouse liver

Article

Author: Kohno, Mamiko ; Kawakami, Hirosato ; Morikawa, Toshio ; Manse, Yoshiaki ; Nagatomo, Akifumi

AbstractAn acylated flavonol glycoside, trans-tiliroside (1), is found in certain parts of different herbs, including the seeds of Rosa canina (Rosaceae). Previous studies on compound 1 have focused on triglyceride (TG) metabolism, including its anti-obesity and intracellular TG reduction effects. In the present study, the effects of compound 1 on cholesterol (CHO) metabolism were investigated using human hepatocellular carcinoma-derived HepG2 cells and mice. Compound 1 decreased CHO secretion in HepG2 cells, which was enhanced by mevalonate in a concentration-dependent manner and decreased the secretion of apoprotein B (apoB)-100, a marker of very low-density lipoprotein (VLDL). Compound 1 also inhibited the activity of microsomal triglyceride transfer proteins, which mediate VLDL formation from cholesterol and triglycerides in the liver. In vivo, compound 1 inhibited the accumulation of Triton WR-1339-induced TG in the blood of fasted mice and maintained low levels of apoB-100. These results suggest that compound 1 inhibits the secretion of CHO as VLDL from the liver and has the potential for use for the prevention of dyslipidemia.Graphical abstract

01 Jan 2022·Computational and Structural Biotechnology Journal

Integrated gut microbiome and metabolome analyses identified fecal biomarkers for bowel movement regulation by Bifidobacterium longum BB536 supplementation: A RCT

Article

Author: Nakamura, Yuya ; Yamada, Takuji ; Umetsu, Junpei ; Mori, Yuka ; Fukuda, Shinji ; Watarai, Naoki ; Nishimoto, Yuichiro ; Higashi, Koichi ; Suzuki, Shinya ; Kohno, Mamiko ; Ishii, Chiharu ; Murakami, Shinnosuke ; Ito, Yutaro

BackgroundBifidobacterium longum BB536 supplementation can be used to regulate bowel movements in various people, including healthy subjects and patients with irritable bowel syndrome (IBS); however, individuals vary in their responses to B. longum BB536 treatment. One putative factor is the gut microbiota; recent studies have reported that the gut microbiota mediates the effects of diet or drugs on the host. Here, we investigated intestinal features, such as the microbiome and metabolome, related to B. longum BB536 effectiveness in increasing bowel movement frequency.ResultsA randomized, double-blind controlled crossover trial was conducted with 24 adults who mainly tended to be constipated. The subjects received a two-week dietary intervention consisting of B. longum BB536 in acid-resistant seamless capsules or similarly encapsulated starch powder as the placebo control. Bowel movement frequency was recorded daily, and fecal samples were collected at several time points, and analyzed by metabologenomic approach that consists of an integrated analysis of metabolome data obtained using mass spectrometry and microbiome data obtained using high-throughput sequencing. There were differences among subjects in B. longum intake-induced bowel movement frequency. The responders were predicted by machine learning based on the microbiome and metabolome features of the fecal samples collected before B. longum intake. The abundances of eight bacterial genera were significantly different between responders and nonresponders.ConclusionsIntestinal microbiome and metabolome profiles might be utilized as potential markers of improved bowel movement after B. longum BB536 supplementation. These findings have implications for the development of personalized probiotic treatments.

100 Deals associated with Morishita Jintan Co., Ltd.

Login to view more data

100 Translational Medicine associated with Morishita Jintan Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data